NASDAQ Newsroom NASDAQ Investor Relations Listed Companies How our Market Works NASDAQ Corporate www.NASDAQ.com
Nasdaq
Web NASDAQ.com   

NASDAQ Biotechnology Index
Index Value Net Change High Low
883.99  6.59  888.82  876.31 

The NASDAQ Biotechnology Index includes securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.

NASDAQ Composite (COMP)     S&P 500 (SPX)     NASDAQ Biotechnology (NBI)     DJIA (.INDU)

Index returns do not represent actual performance of the NASDAQ Biotechnology Index Fund and are for illustration only. Past performance is no guarantee of future results. For actual performance of the iShares NASDAQ Biotechnology Index Fund, request a prospectus by calling 1-800-iShares (1-800-474-2737) or contact your financial advisor.

Biotechnology Index Security Eligibility Criteria
To be eligible for inclusion in the Index, a security must be listed on the Nasdaq Stock Market and meet the following criteria:

  • the security U.S. listing must be exclusively on the NASDAQ National Market (unless the security was dually listed on another U.S. market prior to January 1, 2004 and has continuously maintained such listing);
  • the issuer of the security must be classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals;
  • the security may not be issued by an issuer currently in bankruptcy proceedings;
  • the security must have a market capitalization of at least $200 million;
  • the security must have an average daily trading volume of at least 100,000 shares;
  • the issuer of the security may not have entered into a definitive agreement or other arrangement which would likely result in the security no longer being Index;
  • the issuer of the security may not have annual financial statements with an audit opinion that is currently withdrawn; and
  • the issuer of the security must have "seasoned" on NASDAQ or another recognized market for at least 6 months; in the case of spin-offs, the operating history of the spin-off will be considered.
* For the purposes of Index eligibility criteria, if the security is a depositary receipt representing a security of a non-U.S. issuer, then references to the "issuer" are references to the issuer of the underlying security.

Semi-annual Ranking Review
The Index Securities are evaluated semi-annually as follows. Securities currently within the Index must meet the maintenance criteria of $100 million in market capitalization and 50,000 shares average daily trading volume. Index securities not meeting the maintenance criteria are retained in the Index provided that such security met the maintenance criteria in the previous semi-annual ranking. Securities not meeting the maintenance criteria for two consecutive rankings are removed. Index-eligible securities not currently in the Index are added. Changes will occur after the close of trading on the third Friday in May and November. The data used in the ranking includes end of March and September NASDAQ market data and is updated for total shares outstanding submitted in a publicly filed SEC document via EDGAR through the end of April and October.

In addition to the Ranking Review, the securities in the Index are monitored every day by NASDAQ with respect to changes in total shares outstanding arising from secondary offerings, stock repurchases, conversions, or other corporate actions. NASDAQ has adopted the following weight adjustment procedures with respect to such changes. Changes in total shares outstanding arising from stock splits, stock dividends, or spin-offs are generally made to the Index on the evening prior to the effective date of such corporate action. If the change in total shares outstanding arising from other corporate actions is greater than or equal to 5.0%, the change will be made as soon as practicable, normally within ten (10) days of such action. Otherwise, if the change in total shares outstanding is less than 5%, then all such changes are accumulated and made effective at one time on a quarterly basis after the close of trading on the third Friday in each of March, June, September, and December. In either case, the Index share weights for such Index Securities are adjusted by the same percentage amount by which the total shares outstanding have changed in such Index Securities.

For more information about this and other index based products check our Exchange Traded Funds area.


Data as of Aug. 27, 08 Mkt Close.
Click on the security's symbol for a Full Quote.

Company Name Symbol
ACADIA Pharmaceuticals Inc. ACAD
Acorda Therapeutics, Inc. ACOR
Adolor Corporation ADLR
Affymetrix, Inc. AFFX
Akorn, Inc. AKRX
Albany Molecular Research, Inc. AMRI
Alexion Pharmaceuticals, Inc. ALXN
Alexza Pharmaceuticals, Inc. ALXA
Alkermes, Inc. ALKS
Allos Therapeutics, Inc. ALTH
Alnylam Pharmaceuticals, Inc. ALNY
Altus Pharmaceuticals Inc. ALTU
AMAG Pharmaceuticals, Inc. AMAG
Amgen Inc. AMGN
Amylin Pharmaceuticals, Inc. AMLN
Angiotech Pharmaceuticals, Inc. ANPI
Antigenics Inc. AGEN
APP Pharmaceuticals APPX
Arena Pharmaceuticals, Inc. ARNA
ARIAD Pharmaceuticals, Inc. ARIA
ArQule, Inc. ARQL
Array BioPharma Inc. ARRY
Auxilium Pharmaceuticals, Inc. AUXL
AVI BioPharma, Inc. AVII
BELLUS Health Inc. BLUS
BioCryst Pharmaceuticals, Inc. BCRX
Biodel Inc. BIOD
Biogen Idec Inc BIIB
BioMarin Pharmaceutical Inc. BMRN
BioMimetic Therapeutics, Inc. BMTI
BMP Sunstone Corporation BJGP
Cadence Pharmaceuticals, Inc. CADX
Caliper Life Sciences Inc CALP
Cardiome Pharma Corporation CRME
Celgene Corporation CELG
Cell Genesys, Inc. CEGE
Cell Therapeutics, Inc. CTIC
Cephalon, Inc. CEPH
Cerus Corporation CERS
Columbia Laboratories, Inc. CBRX
CombinatoRx, Incorporated CRXX
Crucell NV CRXL
Cubist Pharmaceuticals, Inc. CBST
CV Therapeutics, Inc. CVTX
Cypress Bioscience, Inc. CYPB
Cytokinetics, Incorporated CYTK
deCODE genetics, Inc. DCGN
Dendreon Corporation DNDN
DepoMed, Inc. DEPO
Discovery Laboratories, Inc. DSCO
Durect Corporation DRRX
Dyax Corp. DYAX
Dynavax Technologies Corporation DVAX
Endo Pharmaceuticals Holdings Inc. ENDP
Enzon Pharmaceuticals, Inc. ENZN
EPIX Pharmaceuticals, Inc. EPIX
Eurand N.V. EURX
Exelixis, Inc. EXEL
Flamel Technologies S.A. FLML
Gen-Probe Incorporated GPRO
Genomic Health, Inc. GHDX
GenVec, Inc. GNVC
Genzyme Corporation GENZ
Geron Corporation GERN
Gilead Sciences, Inc. GILD
GTx, Inc. GTXI
Halozyme Therapeutics, Inc. HALO
Harvard Bioscience, Inc. HBIO
Hi-Tech Pharmacal Co., Inc. HITK
Human Genome Sciences, Inc. HGSI
Idenix Pharmaceuticals, Inc. IDIX
Illumina, Inc. ILMN
ImClone Systems Incorporated IMCL
ImmunoGen, Inc. IMGN
Immunomedics, Inc. IMMU
Incyte Corporation INCY
Indevus Pharmaceuticals Inc. IDEV
Inspire Pharmaceuticals, Inc. ISPH
InterMune, Inc. ITMN
Introgen Therapeutics, Inc. INGN
Invitrogen Corporation IVGN
Isis Pharmaceuticals, Inc. ISIS
ISTA Pharmaceuticals, Inc. ISTA
Lexicon Pharmaceuticals, Inc. LXRX
Ligand Pharmaceuticals Incorporated LGND
Luminex Corporation LMNX
MannKind Corporation MNKD
Matrixx Initiatives Inc. MTXX
Maxygen, Inc. MAXY
MDRNA, Inc. MRNA
Medarex, Inc. MEDX
Medicines Company (The) MDCO
Medivation, Inc. MDVN
MiddleBrook Pharmaceuticals, Inc. MBRK
Momenta Pharmaceuticals, Inc. MNTA
Monogram Biosciences, Inc. MGRM
Myriad Genetics, Inc. MYGN
Nabi Biopharmaceuticals NABI
Nektar Therapeutics NKTR
Neurocrine Biosciences, Inc. NBIX
Novavax, Inc. NVAX
Noven Pharmaceuticals, Inc. NOVN
NPS Pharmaceuticals, Inc. NPSP
Nuvelo, Inc. NUVO
Obagi Medical Products, Inc. OMPI
Omrix Biopharmaceuticals, Inc. OMRI
ONYX Pharmaceuticals, Inc. ONXX
Orchid Cellmark Inc. ORCH
Orexigen Therapeutics, Inc. OREX
OSI Pharmaceuticals Inc. OSIP
Osiris Therapeutics, Inc. OSIR
Pain Therapeutics PTIE
PDL BioPharma, Inc. PDLI
Penwest Pharmaceuticals Co. PPCO
Perrigo Company PRGO
Pharmasset, Inc. VRUS
Pozen, Inc. POZN
Progenics Pharmaceuticals Inc. PGNX
Qiagen N.V. QGEN
QLT Inc. QLTI
Regeneron Pharmaceuticals, Inc. REGN
Rigel Pharmaceuticals, Inc. RIGL
Salix Pharmaceuticals, Ltd. SLXP
Sangamo BioSciences, Inc. SGMO
Santarus, Inc. SNTS
Savient Pharmaceuticals Inc SVNT
Sciele Pharma, Inc. SCRX
Seattle Genetics, Inc. SGEN
Sepracor Inc. SEPR
Sequenom, Inc. SQNM
Shire Limited SHPGY
StemCells, Inc. STEM
SuperGen, Inc. SUPG
Synta Pharmaceuticals Corp. SNTA
Techne Corporation TECH
Telik, Inc. TELK
Tercica, Inc. TRCA
Teva Pharmaceutical Industries Limited TEVA
Theravance, Inc. THRX
Trimeris, Inc. TRMS
United Therapeutics Corporation UTHR
Vanda Pharmaceuticals Inc. VNDA
Vertex Pharmaceuticals Incorporated VRTX
ViroPharma Incorporated VPHM
Vivus, Inc. VVUS
Warner Chilcott Limited WCRX
XenoPort, Inc. XNPT
XOMA Ltd. XOMA
ZymoGenetics, Inc. ZGEN

In addition to the normal risks associated with equity investing, narrowly focused investments and investments in smaller companies typically exhibit higher volatility. Products of companies in which biotechnology funds invest may be subject to severe competition and rapid obsolescence.